Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence

BMC Dermatology

Table 4 Disease morphology at start of treatment (baseline) and at Week 12 or withdrawal (endpoint), by last treatment prescribed^a.

	Methotrexate (N = 13)	Cyclosporine (N = 8)	Corticosteroids (N = 4)	Combined^b(N = 2)	All patients (N = 27)
Inflammatory (n (%))
Baseline	11/13 (84.6)	6/8 (75.0)	2/4 (50.0)	2/2 (100)	21/27 (77.8)
Week 12	1/12^c (8.3)	3/8 (37.5)	0/4 (0.0)	1/2 (50.0)	5/26^c (19.2)
Plaque (n (%))
Baseline	7/13 (53.8)	7/8 (87.5)	4/4 (100)	2/2 (100)	23/27 (85.2)
Week 12	12/12^c (100)	7/8 (87.5)	4/4 (100)	2/2 (100)	25/26^c (96.2)
Papular/pustular (n (%))
Baseline	8/13 (61.5)	3/8 (37.5)	1/4 (25.0)	1/2 (50.0)	13/27 (48.1)
Week 12	2/12^c (16.7)	3/8 (37.5)	0/4 (0)	1/2 (50.0)	6/26^c (23.1)
Inverse (n (%))
Baseline	1/13 (7.7)	0/8 (0.0)	1/4 (25.0)	0/2 (0.0)	2/27 (7.4)
Week 12	1/12^c (8.3)	0/8 (0.0)	0/4 (0.0)	0/2 (0.0)	1/26^c (3.8)
Erythrodermic (n (%))
Baseline	0/13 (0.0)	1/8 (12.5)	0/4 (0.0)	0/2 (0.0)	1/27 (3.7)
Week 12	0/12^c (0.0)	0/8 (0.0)	0/4 (0.0)	0/2 (0.0)	0/26^c (0.0)

^aValues shown are the numbers of patients with the type of morphology as a proportion of the number of patients with available data at baseline. At the investigators' discretion, six patients were switched between treatments during the study. No patient received retinoids at Week 12.
^bCombined systemic corticosteroids plus methotrexate.
^cOne patient withdrew from the study.

ISSN: 1471-5945